Login to Your Account

Acorda Builds on Ampyra Sales; Gains Option to Buy Neuronex

By Marie Powers
Staff Writer

Friday, February 17, 2012
Boosted by 2011 net revenues of $210.5 million in the U.S., including fourth-quarter net revenues of $57.2 million, thanks to sales of Ampyra (dalfampridine) extended-release tablets, Acorda Therapeutics Inc. said Thursday it inked a deal to acquire privately held Neuronex Inc., which is developing a nasal spray formulation of diazepam for certain epilepsy patients.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription